[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @HOThomasWPhelps In Honour Of Thomas W Phelps Corvus Pharmaceuticals ($CRVS) is gaining attention in the atopic dermatitis treatment space with its oral ITK inhibitor, Soquelitinib, showing promising results. The company has been expanding its growth plans, with multiple new job postings, and has garnered significant interest from bio funds, including Point72, which increased its position in $CRVS by 153%. $CRVS is a leader in this space with a comprehensive control of multiple pathways. ### Engagements: XXXXX [#](/creator/twitter::1839941677336936448/interactions)  - X Week XXXXXX +183% - X Month XXXXXXX +0.87% - X Months XXXXXXX +69% - X Year XXXXXXXXX +320% ### Mentions: XX [#](/creator/twitter::1839941677336936448/posts_active)  - X Week XX -XX% - X Month XX -XX% - X Months XXX -XXXX% - X Year XXX +284% ### Followers: XXXXX [#](/creator/twitter::1839941677336936448/followers)  - X Week XXXXX +1.10% - X Month XXXXX +5.30% - X Months XXXXX +134% - X Year XXXXX +324% ### CreatorRank: XXXXXXXXX [#](/creator/twitter::1839941677336936448/influencer_rank)  ### Social Influence **Social category influence** [stocks](/list/stocks) XXXXX% [finance](/list/finance) XXX% [cryptocurrencies](/list/cryptocurrencies) XXXX% **Social topic influence** [$kymr](/topic/$kymr) #9, [$crvs](/topic/$crvs) #1, [1b](/topic/1b) #47, [$abbv](/topic/$abbv) 6.9%, [target](/topic/target) 6.9%, [$lly](/topic/$lly) #58, [$mrk](/topic/$mrk) #49, [market cap](/topic/market-cap) #214, [i know](/topic/i-know) 3.45%, [$xbi](/topic/$xbi) XXXX% **Top accounts mentioned or mentioned by** [@financebully](/creator/undefined) [@kvgr87](/creator/undefined) [@wjhuber5](/creator/undefined) [@pmillustration4](/creator/undefined) [@solariumearth](/creator/undefined) [@andreagtc](/creator/undefined) [@trentkelp](/creator/undefined) [@yolomoonlambo](/creator/undefined) [@jacobplieth](/creator/undefined) [@apexonco](/creator/undefined) [@endpts](/creator/undefined) [@mtheory11bio](/creator/undefined) [@biopharmiq](/creator/undefined) [@faso171](/creator/undefined) [@buymoremakemore](/creator/undefined) [@stvrosb](/creator/undefined) **Top assets mentioned** [Kymera Therapeutics, Inc. Common Stock (KYMR)](/topic/$kymr) [AbbVie Inc (ABBV)](/topic/$abbv) [Eli Lilly and Company (LLY)](/topic/$lly) [Merck & Co., Inc. (MRK)](/topic/$mrk) [Bitcoin Incognito (XBI)](/topic/$xbi) [Klaydice (DICE)](/topic/$dice) [Prometheus Biosciences, Inc. Common Stock (RXDX)](/topic/$rxdx) [Alpine Immune Sciences, Inc. Common Stock (ALPN)](/topic/$alpn) [Vertex Protocol (VRTX)](/topic/$vrtx) [Synthetify (SNY)](/topic/$sny) [Regeneron Pharmaceuticals Inc (REGN)](/topic/$regn) ### Top Social Posts Top posts by engagements in the last XX hours "Here is the updated table showing $KYMR Ph 1b Atopic Dermatitis data v #Dupilumab and $CRVS ITK inhibitor #soquelitinib as novel MOA two oral therapies. Note there is no PBO control for $KYMR $CRVS has higher EASI-75 reductions closer to JAKi while $KYMR seems to match Dupi" [X Link](https://x.com/HOThomasWPhelps/status/1998002675485401122) 2025-12-08T12:12Z 1885 followers, 22.1K engagements "$CRVS - Safe to say #ITK is on $ABBV radar for AD New paper AbbVie in June 2024 identified XX new gene loci involved in atopic dermatitis: 🔹 ITK was the "top-scoring" "prioritized" gene (gene location 5q33.3)" [X Link](https://x.com/HOThomasWPhelps/status/1988189788378460483) 2025-11-11T10:19Z 1866 followers, 5826 engagements "$XBI Short Interest Actually INCREASED in new report Now XXX% of $XBI Float is Short" [X Link](https://x.com/HOThomasWPhelps/status/1993606330938991036) 2025-11-26T09:02Z 1860 followers, 7258 engagements "$CRVS $600M MC Buyouts post Ph 1/2a POC (some open label) while $CRVS Cohort X data in Jan is PBO-controlled randomized w/ good safety - $DICE by $LLY $2.4B Ph X - $RXDX by $MRK $10.8B Ph 2a open label - $ALPN by $VRTX $4.9B Ph 1b/2a - $MORF by $LLY $3.2B Ph 2a open label" [X Link](https://x.com/HOThomasWPhelps/status/1989253996822061475) 2025-11-14T08:48Z 1872 followers, 9760 engagements "Table comparing oral drugs in atopic dermatitis w/ data in Nov/Dec w/ #Dupilumab Ph X 4-wk EASI data $CRVS: oral ITK Inhibitor Cohort 1-3 EASI reductions already better than dupi waiting on Cohort X 8-wk data $KYMR: oral KT-621 #STAT6 degrader TBD no placbo" [X Link](https://x.com/HOThomasWPhelps/status/1984259690961031609) 2025-10-31T14:02Z 1872 followers, 9701 engagements "@wjhuber5 @KVGR87 Agree $KYMR #STAT6 is downstream of dupi and JAKi pathways and those refractory patients can not benefit from KT-621 which is large opportunity for novel MOA like $CRVS soquelitinib separate from JAKi or IL-4/13 pathway blockade" [X Link](https://x.com/HOThomasWPhelps/status/1998009739628720351) 2025-12-08T12:40Z 1885 followers, XXX engagements "@financebully There is much for the market and investors to digest here between $CRVS and $KYMR. I look forward to it" [X Link](https://x.com/HOThomasWPhelps/status/1998009955329122619) 2025-12-08T12:41Z 1885 followers, XXX engagements "Update $KYMR pre-market is up XX% and now over $6B in valuation" [X Link](https://x.com/HOThomasWPhelps/status/1998012167501607030) 2025-12-08T12:49Z 1885 followers, XXX engagements "@JacobPlieth @ApexOnco Do you think $NRIX is a sympathy trade with $KYMR STAT6 data today" [X Link](https://x.com/HOThomasWPhelps/status/1998083503037337756) 2025-12-08T17:33Z 1877 followers, XXX engagements "Looking at the two data sets from $CRVS and $KYMR the valuation difference is even more striking Maybe some revaluations in order $KYMR $5B Market Cap $4B EV is 6-7x more than $CRVS $650M MC $590M EV" [X Link](https://x.com/HOThomasWPhelps/status/1998005080457429270) 2025-12-08T12:21Z 1885 followers, 20.6K engagements "Now $KYMR up XX% up another $1B in market cap I lean even harder that $CRVS is a very serious buyout target and could quickly close the valuation gap with $KYMR in such a situation. Both oral therapies both safe both showing similar EASI reduction w/ $CRVS better EASI-75" [X Link](https://x.com/HOThomasWPhelps/status/1998007054875664690) 2025-12-08T12:29Z 1885 followers, 6387 engagements "@KVGR87 Yes $CRVS has years of safety data from PTCL trial some patients been on drug for 2+ years now" [X Link](https://x.com/HOThomasWPhelps/status/1998007895531659466) 2025-12-08T12:32Z 1885 followers, XXX engagements "@endpts $KYMR KT-621 oral #STAT6 degrader EASI EASI-50 EASI-75 and IGA 0/1 compared to Phase X #dupilumab data" [X Link](https://x.com/HOThomasWPhelps/status/1998063776214524053) 2025-12-08T16:15Z 1885 followers, 1114 engagements "$KYMR $CRVS (Ph 1b 4wk data) Oral novel MOA for atopic dermatitis drugs in development 4-wk EASI-75 v FDA approved drugs: $SNY $REGN #Dupilumab $LLY #Lebrikizumab $ABBV #Upadacitinib EASI-75 reduction trends: JAKi = ITKi STAT6 = IL-4Ra = IL-13" [X Link](https://x.com/HOThomasWPhelps/status/1998127682643710300) 2025-12-08T20:28Z 1885 followers, 5884 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@HOThomasWPhelps In Honour Of Thomas W Phelps
Corvus Pharmaceuticals ($CRVS) is gaining attention in the atopic dermatitis treatment space with its oral ITK inhibitor, Soquelitinib, showing promising results. The company has been expanding its growth plans, with multiple new job postings, and has garnered significant interest from bio funds, including Point72, which increased its position in $CRVS by 153%. $CRVS is a leader in this space with a comprehensive control of multiple pathways.
Engagements: XXXXX #
- X Week XXXXXX +183%
- X Month XXXXXXX +0.87%
- X Months XXXXXXX +69%
- X Year XXXXXXXXX +320%
Mentions: XX #
- X Week XX -XX%
- X Month XX -XX%
- X Months XXX -XXXX%
- X Year XXX +284%
Followers: XXXXX #
- X Week XXXXX +1.10%
- X Month XXXXX +5.30%
- X Months XXXXX +134%
- X Year XXXXX +324%
CreatorRank: XXXXXXXXX #
Social Influence
Social category influence stocks XXXXX% finance XXX% cryptocurrencies XXXX%
Social topic influence $kymr #9, $crvs #1, 1b #47, $abbv 6.9%, target 6.9%, $lly #58, $mrk #49, market cap #214, i know 3.45%, $xbi XXXX%
Top accounts mentioned or mentioned by @financebully @kvgr87 @wjhuber5 @pmillustration4 @solariumearth @andreagtc @trentkelp @yolomoonlambo @jacobplieth @apexonco @endpts @mtheory11bio @biopharmiq @faso171 @buymoremakemore @stvrosb
Top assets mentioned Kymera Therapeutics, Inc. Common Stock (KYMR) AbbVie Inc (ABBV) Eli Lilly and Company (LLY) Merck & Co., Inc. (MRK) Bitcoin Incognito (XBI) Klaydice (DICE) Prometheus Biosciences, Inc. Common Stock (RXDX) Alpine Immune Sciences, Inc. Common Stock (ALPN) Vertex Protocol (VRTX) Synthetify (SNY) Regeneron Pharmaceuticals Inc (REGN)
Top Social Posts
Top posts by engagements in the last XX hours
"Here is the updated table showing $KYMR Ph 1b Atopic Dermatitis data v #Dupilumab and $CRVS ITK inhibitor #soquelitinib as novel MOA two oral therapies. Note there is no PBO control for $KYMR $CRVS has higher EASI-75 reductions closer to JAKi while $KYMR seems to match Dupi"
X Link 2025-12-08T12:12Z 1885 followers, 22.1K engagements
"$CRVS - Safe to say #ITK is on $ABBV radar for AD New paper AbbVie in June 2024 identified XX new gene loci involved in atopic dermatitis: 🔹 ITK was the "top-scoring" "prioritized" gene (gene location 5q33.3)"
X Link 2025-11-11T10:19Z 1866 followers, 5826 engagements
"$XBI Short Interest Actually INCREASED in new report Now XXX% of $XBI Float is Short"
X Link 2025-11-26T09:02Z 1860 followers, 7258 engagements
"$CRVS $600M MC Buyouts post Ph 1/2a POC (some open label) while $CRVS Cohort X data in Jan is PBO-controlled randomized w/ good safety - $DICE by $LLY $2.4B Ph X - $RXDX by $MRK $10.8B Ph 2a open label - $ALPN by $VRTX $4.9B Ph 1b/2a - $MORF by $LLY $3.2B Ph 2a open label"
X Link 2025-11-14T08:48Z 1872 followers, 9760 engagements
"Table comparing oral drugs in atopic dermatitis w/ data in Nov/Dec w/ #Dupilumab Ph X 4-wk EASI data $CRVS: oral ITK Inhibitor Cohort 1-3 EASI reductions already better than dupi waiting on Cohort X 8-wk data $KYMR: oral KT-621 #STAT6 degrader TBD no placbo"
X Link 2025-10-31T14:02Z 1872 followers, 9701 engagements
"@wjhuber5 @KVGR87 Agree $KYMR #STAT6 is downstream of dupi and JAKi pathways and those refractory patients can not benefit from KT-621 which is large opportunity for novel MOA like $CRVS soquelitinib separate from JAKi or IL-4/13 pathway blockade"
X Link 2025-12-08T12:40Z 1885 followers, XXX engagements
"@financebully There is much for the market and investors to digest here between $CRVS and $KYMR. I look forward to it"
X Link 2025-12-08T12:41Z 1885 followers, XXX engagements
"Update $KYMR pre-market is up XX% and now over $6B in valuation"
X Link 2025-12-08T12:49Z 1885 followers, XXX engagements
"@JacobPlieth @ApexOnco Do you think $NRIX is a sympathy trade with $KYMR STAT6 data today"
X Link 2025-12-08T17:33Z 1877 followers, XXX engagements
"Looking at the two data sets from $CRVS and $KYMR the valuation difference is even more striking Maybe some revaluations in order $KYMR $5B Market Cap $4B EV is 6-7x more than $CRVS $650M MC $590M EV"
X Link 2025-12-08T12:21Z 1885 followers, 20.6K engagements
"Now $KYMR up XX% up another $1B in market cap I lean even harder that $CRVS is a very serious buyout target and could quickly close the valuation gap with $KYMR in such a situation. Both oral therapies both safe both showing similar EASI reduction w/ $CRVS better EASI-75"
X Link 2025-12-08T12:29Z 1885 followers, 6387 engagements
"@KVGR87 Yes $CRVS has years of safety data from PTCL trial some patients been on drug for 2+ years now"
X Link 2025-12-08T12:32Z 1885 followers, XXX engagements
"@endpts $KYMR KT-621 oral #STAT6 degrader EASI EASI-50 EASI-75 and IGA 0/1 compared to Phase X #dupilumab data"
X Link 2025-12-08T16:15Z 1885 followers, 1114 engagements
"$KYMR $CRVS (Ph 1b 4wk data) Oral novel MOA for atopic dermatitis drugs in development 4-wk EASI-75 v FDA approved drugs: $SNY $REGN #Dupilumab $LLY #Lebrikizumab $ABBV #Upadacitinib EASI-75 reduction trends: JAKi = ITKi STAT6 = IL-4Ra = IL-13"
X Link 2025-12-08T20:28Z 1885 followers, 5884 engagements